ADHD Medications Approved for Adults in 2026

Updated October 13, 2026. Part of the New York Adult ADHD Guide, understand section. Medically reviewed by John C. Shershow, M.D. on October 13, 2026. Editorial policy

Key points

Amphetamine and methylphenidate medications are Schedule II controlled substances, and each family includes products whose FDA labels cover adults.
Atomoxetine and viloxazine are FDA-approved for ADHD in adults and are not controlled substances.
Centanafadine (Simtriyo) was approved by the FDA on July 24, 2026 and is labeled a central nervous system stimulant with two boxed warnings.
Ritalin LA, the Daytrana patch and Onyda XR are labeled for pediatric patients, not adults.
Bupropion and modafinil are not FDA-approved for ADHD, so any use for ADHD is off-label.

Dozens of brand and generic products are sold for ADHD, yet they come down to a small number of active ingredients grouped into a few classes. This article maps those classes using the indication wording on current FDA labels, checked on October 13, 2026. Product names appear as examples of a class and are not recommendations. Which medication suits a particular person is a decision for that person and their prescriber.

How to read an FDA indication

Every prescription drug label has an indications section that states the condition and the age group the FDA reviewed. For ADHD medications the age wording varies: some labels say "adults and pediatric patients 6 years and older," some give an upper age, and some cover children only.

Prescribing a drug outside its labeled age range or condition is called off-label use. It means the label does not cover that use, which is worth knowing when you compare options.

The classes at a glance

Class	Example active ingredients	Controlled substance?	Adult labeling
Stimulant, amphetamine family	Mixed amphetamine salts, lisdexamfetamine, dextroamphetamine, amphetamine	Yes, Schedule II	Yes for several products
Stimulant, methylphenidate family	Methylphenidate, dexmethylphenidate, serdexmethylphenidate with dexmethylphenidate	Yes, Schedule II	Yes for several products. Some labels stop at age 65
Non-stimulant	Atomoxetine, viloxazine	No	Yes
New in 2026	Centanafadine	Scheduling pending	Yes, but not yet available

Stimulants: the amphetamine family

Current labels for these amphetamine products include adults or have no upper age limit:

Mixed amphetamine salts, extended-release capsules (Adderall XR): ADHD "in adults and pediatric patients 6 years and older."
Mixed amphetamine salts, immediate-release tablets (Adderall): indicated for ADHD and narcolepsy.
Lisdexamfetamine (Vyvanse): ADHD in adults and pediatric patients 6 and older, and also moderate to severe binge eating disorder in adults.
Dextroamphetamine transdermal system (Xelstrym): a skin patch, labeled for adults and pediatric patients 6 and older.
Amphetamine extended-release (Dyanavel XR): patients 6 years and older.
Another mixed amphetamine salts extended-release product (Mydayis): patients 13 years and older.

Two older products, amphetamine sulfate (Evekeo) and dextroamphetamine sulfate tablets (Zenzedi), have ADHD indications worded for children. Using them for adult ADHD falls outside the labeled age wording.

Stimulants: the methylphenidate family

Methylphenidate extended-release tablets (Concerta): ADHD "in patients aged 6 to 65 years old." A similar product (Relexxii) is labeled for adults up to age 65.
Methylphenidate immediate-release (Ritalin): pediatric patients 6 and older and adults, and also narcolepsy.
Methylphenidate oral solution (Methylin): adults and pediatric patients 6 and older.
Evening-dosed methylphenidate extended-release (Jornay PM): patients 6 years and older.
Serdexmethylphenidate with dexmethylphenidate (Azstarys): patients 6 years and older.
Dexmethylphenidate (Focalin, Focalin XR) and a methylphenidate extended-release suspension (Quillivant XR): indicated for ADHD without a stated upper age.

Two methylphenidate products are not labeled for adults: Ritalin LA (pediatric patients 6 to 12) and the Daytrana patch (pediatric patients 6 to 17).

All stimulants in both families carry the same FDA boxed warning about abuse, misuse and addiction, which the FDA required across the class on May 11, 2023. Because they are Schedule II drugs, they fall under New York's tightest prescription rules: no refills and limits on supply and early fills.

Non-stimulants

Atomoxetine (Strattera and generics): ADHD "in adults and pediatric patients 6 years of age and older." It is not a controlled substance. Its boxed warning concerns suicidal thoughts and behaviors in pediatric patients.
Viloxazine (Qelbree): ADHD in adults and pediatric patients 6 and older. It is not a controlled substance and carries a boxed warning about suicidal thoughts and behaviors.

Other non-stimulants come up often but should not be described as adult-approved. Clonidine extended-release oral suspension (Onyda XR) is labeled for pediatric patients only. Guanfacine extended-release (Intuniv) is indicated for ADHD alone or alongside a stimulant, but the age range on its label was not confirmed for this guide, and it is generally described as a pediatric approval.

Bupropion and modafinil are not FDA-approved for ADHD. If a prescriber suggests one, that is off-label use, and it is reasonable to ask why it is being considered. The existing article on non-stimulant ADHD medications goes further into this group.

New in 2026: centanafadine (Simtriyo)

The FDA approved Simtriyo (centanafadine) extended-release capsules, made by Otsuka, on July 24, 2026. According to the manufacturer, it is indicated for ADHD in adults and in pediatric patients 6 and older above a minimum body weight, and it is taken once daily.

Three points are often reported wrongly:

It is labeled a stimulant. The manufacturer describes it as "a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant." News coverage that calls it a non-stimulant does not match the label.
It has two boxed warnings, one on suicidal ideation and behaviors in pediatric patients and one on abuse, misuse and addiction.
It is not in pharmacies yet. The manufacturer said it expects availability later in 2026 "following scheduling by the U.S. Drug Enforcement Administration." As of October 13, 2026, no DEA scheduling action for centanafadine had appeared in the Federal Register.

Which schedule the DEA will assign, and the launch date, are not known. The schedule matters in New York because it determines which prescription rules apply. No other new ADHD product for adults approved between 2024 and 2026 was found for this guide, though a complete sweep of FDA approvals was not carried out.

What the evidence says about the classes

In a 2018 network meta-analysis of 133 double-blind trials published in Lancet Psychiatry, amphetamines, methylphenidate and atomoxetine each reduced adult ADHD symptoms more than placebo at about 12 weeks, with the largest effect for amphetamines, and modafinil was not better than placebo. A 2025 analysis of 113 trials found that only stimulants and atomoxetine reduced core symptoms on both self-ratings and clinician ratings. Both analyses measured about 12 weeks and say little about long-term outcomes. Does ADHD treatment work in adults? explains the numbers.

Labels change. Indications and warnings are revised from time to time. The FDA label for any product is the authoritative source, and your pharmacist can provide the current Medication Guide.

Where to go next

Knowing the classes is the first step. The practical differences between them in New York come from the law: stimulants are subject to supply limits, a ban on refills and a registry check, while atomoxetine and viloxazine are not. The next article to read is New York's rules for ADHD stimulant prescriptions, which compares those rules in one table. For safety questions, see ADHD medication, heart health and blood pressure. General reading is collected in the treatment and medication hub.

Questions

What is the difference between stimulant and non-stimulant ADHD medication?

Stimulants are the amphetamine and methylphenidate medications, which are Schedule II controlled substances. Atomoxetine and viloxazine are non-stimulants approved for adults and are not controlled substances. The legal difference affects refills, supply limits and monitoring in New York.

Is Simtriyo (centanafadine) available in New York pharmacies?

Not as of October 13, 2026. The FDA approved it on July 24, 2026, but it cannot be dispensed until the DEA assigns it a schedule, and no scheduling action had been published by that date.

Is centanafadine a non-stimulant?

No. The manufacturer's description of the approved product calls it a central nervous system stimulant, and it carries a boxed warning about abuse, misuse and addiction.

Are guanfacine and clonidine approved for adult ADHD?

Clonidine extended-release oral suspension (Onyda XR) is labeled for pediatric patients only. The age range on the guanfacine extended-release label was not confirmed for this guide, and it is generally described as approved for children and adolescents. Use in adults would be off-label.

Is bupropion approved for ADHD?

No. Bupropion is not FDA-approved for ADHD, so prescribing it for ADHD is off-label. A 2024 review in American Family Physician lists it among non-stimulant options when stimulants are unsuitable, while noting the lack of FDA approval.

Why do some ADHD medication labels stop at age 65?

The labels for certain methylphenidate extended-release tablets state an indication for patients up to 65 years old, which reflects the age group covered by the label's wording. A prescriber can discuss what that means for an older adult.

Sources

This article is general information, not medical or legal advice. Rules and coverage change; check the linked sources for the current position, and speak with a clinician or attorney about your own situation.

ADHD medications approved for adults in 2026